- Ceapro (TSXV:CZO) has begun a Phase 1 study of its flagship product for managing conditions related to inflammation
- The study is a double-blind, placebo-controlled first-in-human study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of the treatment
- Roughly 72 patients will be enrolled in the first phase of the trial
- Shares of Ceapro are unchanged at C$0.28
Ceapro (TSXV:CZO) has launched a Phase 1 study evaluating its flagship product avenanthramides in managing inflammation-related conditions.
In a news release, the company stated the study is double-blind and placebo-controlled, and it is the first-in-human study of the product to assess the safety, tolerability and pharmacokinetics of single and multiple oral doses.
Roughly 72 patients will be enrolled in the first phase of the study. The single ascending dose (SAD) arm will include six cohorts of eight healthy patients. The multiple ascending dose (MAD) arm will include three cohorts of eight healthy patients.
Once phase 1 is complete, the AvenActive protocol includes a Phase2a portion for patients who have presented mild-to-moderate inflammation. Roughly 24 patients will be enrolled in the second phase of the study.
“Ceapro is thrilled to advance this groundbreaking research. A number of studies have suggested that avenanthramides may exert anti-inflammatory effects on the vascular system through various mechanisms and we look forward to better decipher those pathways,” Giles Gagnon, CEO of Ceapro, said in a statement. “Initiation of this study marks another step in expanding our business as a biopharmaceutical company.”
Patient dosing is expected to begin next month.
Ceapro’s avenanthramides flagship product is a group of phenolic alkaloids sourced from oats and produced using a patented process.
Avenanthramides treat a range of skin conditions including eczema, allergic rash, chicken pox and insect bites.
With headquarters in Edmonton, Ceapro is a biotechnology company that develops proprietary extraction technology to extract active ingredients from oats and other renewable plant sources.
Shares of Ceapro are unchanged at C$0.28.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.